BACKGROUND: Coronary revascularization using percutaneous coronary intervention (PCI) is one of the major treatments for patients with stable coronary artery disease, with approximately 1.5 million patients undergoing PCI in the United States and Europe every year. An important neglected complication of PCI is contrast-induced acute kidney injury (CI-AKI). DESIGN: In this article, we review the definition, pathogenesis and management of CI-AKI and highlight potential therapeutic options for preventing CI-AKI in post-PCI patients. RESULTS: CI-AKI is an important but underdiagnosed complication of PCI that is associated with increased in-hospital morbidity and mortality. Patients with pre-existing renal impairment and diabetes are particularly susceptible to this complication post-PCI. Optimization of the patients' circulating volume remains the mainstay for preventing CI-AKI, although the best strategy for achieving this is still controversial. CONCLUSION: Following PCI, CI-AKI is an overlooked complication which is associated with significant morbidity and mortality. In this article, we review the pathophysiology of CI-AKI in patients undergoing PCI and discuss the potential therapeutic options for preventing it.
BACKGROUND: Coronary revascularization using percutaneous coronary intervention (PCI) is one of the major treatments for patients with stable coronary artery disease, with approximately 1.5 million patients undergoing PCI in the United States and Europe every year. An important neglected complication of PCI is contrast-induced acute kidney injury (CI-AKI). DESIGN: In this article, we review the definition, pathogenesis and management of CI-AKI and highlight potential therapeutic options for preventing CI-AKI in post-PCI patients. RESULTS: CI-AKI is an important but underdiagnosed complication of PCI that is associated with increased in-hospital morbidity and mortality. Patients with pre-existing renal impairment and diabetes are particularly susceptible to this complication post-PCI. Optimization of the patients' circulating volume remains the mainstay for preventing CI-AKI, although the best strategy for achieving this is still controversial. CONCLUSION: Following PCI, CI-AKI is an overlooked complication which is associated with significant morbidity and mortality. In this article, we review the pathophysiology of CI-AKI in patients undergoing PCI and discuss the potential therapeutic options for preventing it.
Authors: Nachiket Patel; Sarah M Baker; Ryan W Walters; Ajay Kaja; Vimalkumar Kandasamy; Ahmed Abuzaid; Ariel M Modrykamien Journal: Proc (Bayl Univ Med Cent) Date: 2016-01
Authors: E Katsogridakis; T Lea; T Yap; A Batchelder; P Saha; A Diamantopoulos; N Saratzis; R Davies; H Zayed; M J Bown; A Saratzis Journal: Br J Surg Date: 2021-03-12 Impact factor: 6.939
Authors: Marie Dam Lauridsen; Henrik Gammelager; Morten Schmidt; Thomas Bøjer Rasmussen; Richard E Shaw; Hans Erik Bøtker; Henrik Toft Sørensen; Christian Fynbo Christiansen Journal: Crit Care Date: 2015-12-30 Impact factor: 9.097
Authors: Rene A Posma; Chris P H Lexis; Erik Lipsic; Maarten W N Nijsten; Kevin Damman; Daan J Touw; Dirk Jan van Veldhuisen; Pim van der Harst; Iwan C C van der Horst Journal: Cardiovasc Drugs Ther Date: 2015 Impact factor: 3.727